Immunotherapy News and Research

Latest Immunotherapy News and Research

Increased risk of cardiovascular disease in psoriatic arthritis patients

Increased risk of cardiovascular disease in psoriatic arthritis patients

Novel approach improves the efficacy of immune checkpoint blockade and minimizes related side effects

Novel approach improves the efficacy of immune checkpoint blockade and minimizes related side effects

Scientists develop new immuno-therapeutic approach to target brain metastatic melanomas

Scientists develop new immuno-therapeutic approach to target brain metastatic melanomas

New pan-cancer T cell atlas provides a deeper understanding of complex tumor microenvironment

New pan-cancer T cell atlas provides a deeper understanding of complex tumor microenvironment

2023 PCRF grant recipients announced for exploring new, safer treatments for pediatric cancers

2023 PCRF grant recipients announced for exploring new, safer treatments for pediatric cancers

Using nanoparticles and magnetic field to guide immunotherapy cells

Using nanoparticles and magnetic field to guide immunotherapy cells

Case study: Experimental lecanemab treatment causes adverse outcomes in 65-year-old woman with Alzheimer's disease

Case study: Experimental lecanemab treatment causes adverse outcomes in 65-year-old woman with Alzheimer's disease

First-in-human nanoparticle HIV vaccine induces broad and publicly targeted helper T cell responses

First-in-human nanoparticle HIV vaccine induces broad and publicly targeted helper T cell responses

Cancer researchers join together to fight lethal childhood brain cancer

Cancer researchers join together to fight lethal childhood brain cancer

The role of RNA splicing in one of the deadliest forms of pancreatic cancer

The role of RNA splicing in one of the deadliest forms of pancreatic cancer

Researchers receive $2.3 million to continue development of a new ‘glyco-immune’ checkpoint inhibitor

Researchers receive $2.3 million to continue development of a new ‘glyco-immune’ checkpoint inhibitor

Novel computational platform can expand the pool of cancer immunotherapy targets

Novel computational platform can expand the pool of cancer immunotherapy targets

Researchers discover key epigenetic alteration associated with clinical course of liver cancer

Researchers discover key epigenetic alteration associated with clinical course of liver cancer

Cancer patients can initiate SARS-CoV-2 vaccination three months after bone marrow transplant

Cancer patients can initiate SARS-CoV-2 vaccination three months after bone marrow transplant

PhenomeX Launches Beacon Select™ Optofluidic System with Opto® B Discovery Workflows

PhenomeX Launches Beacon Select™ Optofluidic System with Opto® B Discovery Workflows

Clinical trial of a combination treatment shows great promise for patients with glioblastoma

Clinical trial of a combination treatment shows great promise for patients with glioblastoma

Phase 1 clinical trial of CAR-NKT cell therapy shows promising results in neuroblastoma patients

Phase 1 clinical trial of CAR-NKT cell therapy shows promising results in neuroblastoma patients

Combination approach is safe, improves survival outcomes in a subset of glioblastoma patients

Combination approach is safe, improves survival outcomes in a subset of glioblastoma patients

Pioneering focused ultrasound trial shows promising results for patients with Parkinson’s disease

Pioneering focused ultrasound trial shows promising results for patients with Parkinson’s disease

Newly identified biomarker may predict NSCLC patients' treatment response to chemoimmunotherapy

Newly identified biomarker may predict NSCLC patients' treatment response to chemoimmunotherapy

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.